Peptides to Overcome the Limitations of Current Anticancer and Antimicrobial Nanotherapies

Biomedical research devotes a huge effort to the development of efficient non-viral nanovectors (NV) to improve the effectiveness of standard therapies. NVs should be stable, sustainable and biocompatible and enable controlled and targeted delivery of drugs. With the aim to foster the advancements o...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 14; no. 6; p. 1235
Main Authors Del Genio, Valentina, Bellavita, Rosa, Falanga, Annarita, Hervé-Aubert, Katel, Chourpa, Igor, Galdiero, Stefania
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 10.06.2022
MDPI
Subjects
anticancer
antimicrobial
Antimicrobial agents
Bioavailability
Blood
Cancer
Drug delivery systems
drug release
Drug resistance
Nanoparticles
Nanotechnology
nanovectors
peptide
Peptides
Polyethylene glycol
Review
Tumors
antimicrobial
nanovectors
peptide
drug release
anticancer
Online AccessGet full text

Cover

More Information
Summary:Biomedical research devotes a huge effort to the development of efficient non-viral nanovectors (NV) to improve the effectiveness of standard therapies. NVs should be stable, sustainable and biocompatible and enable controlled and targeted delivery of drugs. With the aim to foster the advancements of such devices, this review reports some recent results applicable to treat two types of pathologies, cancer and microbial infections, aiming to provide guidance in the overall design of personalized nanomedicines and highlight the key role played by peptides in this field. Additionally, future challenges and potential perspectives are illustrated, in the hope of accelerating the translational advances of nanomedicine.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14061235